The Nasdaq has become “a tale of two cities” with haves and have-nots.
That relationship shifts daily.
As such, it is getting too hard to trade.
For the foreseeable future I will be concentrating on shoring the S&P index.
I am no longer short QQQ.
Position: Short SPY (VS)
With S&P cash +11 handles, I am back shorting SPY at $748.22.
Position: Short SPY (VS)
Here’s why this subscription healthcare and lifestyle company could muscle up soon — and why you should proceed with caution.
Another leg lower for momentum, high beta tech (part of my short basket).
I am sticking with the remainder of the basket even though some of the drops have been dramatic:
Today’s Selected Price Changes in Short Basket
* SNDK ($SNDK) -$255
* CAT ($CAT) -$58
* CRWV ($CRWV) -$15
* INTC ($INTC) -$11
* MU ($MU) -$98
Position: Short Basket
Sometime in the next six months cannabis equities will become meme stocks.
Positions: Long Cannabis
I have 14 longs and 24 shorts in my hedge fund’s portfolio currently.
An overbought condition also prompts a rating downgrade.
Here’s how we’re locking in gains without abandoning a big winner.
PPermaUnsure
3m ago
I’ve always found it strange that some people think it’s wrong to identify fundamental problems before they cause harm. If a doctor identifies cancer while it’s at an early stage, people don’t laugh at him and say “you’re early, and early is the same as being wrong.” Instead, the doctor is praised. Identifying the existence of a cancer and predicting the time that the cancer will kill the patient are two completely different things.ReplyShare
none
